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1. Introduction
The oligometastasic disease concept was proposed by Hell-
man and Weichselbaum in 1995 as a third hypothesis of the
pathogenesis of cancer.1
The classic dilemma between tumors that could be cured
with local treatment, surgery and/or radiotherapy because
the tumors were partly spread and the metastatic disease
mostly could only be treated with systemic palliative treat-
ment, may be completed with a third theory: some tumors
and metastatic disease could be treated with local treatment
with curative intention. The dissemination of certain tumors
would be done in a controlled and limited way that would
allow the use of surgery, radiotherapy and other ablative treat-
ments. This approach has been demonstrated in the central
nervous systemmetastases treatedwith surgery, radiotherapy
and radiosurgery, as well as liver and lung metastasis treated
with surgery. The same authors participated in a clinical trial
with 60 patientswith 113metastaseswhere radiotherapy dose
titration was prospectively studied between November 2004
and November 2009.2 The progression-free survival at two
years was 22% and the overall survival at two years was 56.7%.
Eleven patients (18.3%) did not progress. The importance of
this approach is determined by better selection of patients
with more precise techniques, to study the contribution of
systemic treatments, and also increase the knowledge of the
metastatic process. Current understanding about the com-
plexity of tumor biology can overcome the classical theory
of Halsted where the spread was done in an orderly spread-
ing to contiguous regions such as lymph nodes and later
to distance.3 The subsequent theory of Bernard Fisher and
colleagues suggesting the need for chemotherapy for most
patients to treat cancer of a more systemic than local is also
overcome by clinical observations.4 But since the “seed and
soil” Paget’s hypothesis where the metastasis depends on
interaction of the tumor cell and the host microenvironment,
the advancement of knowledge does not allow prediction of
the behavior of the most tumors.3
The main issue is to understand the biology of the
oligometastatic phenotype, if it really exists. Just as there
are already tests for selecting patients and avoid adju-
vant chemotherapy, we have no tools to ascertain the
oligometastatic situation.5 Lussier and colleagues analyzed
the expression of microRNAs in lung metastases in patients
with less than 5 metastases and curative treated classiﬁed
according to the percentage of recurrence.6 The selected
microRNAs were able to distinguish between high and low
probability of disease recurrence in a series of validation,
establishing a molecular hypothesis oligometastatic disease.
However, the great heterogeneity of tumors is responsible
for the large clinical and molecular variability, forcing us to
reevaluate the metastatic cascade. A small proportion of can-
cer cells, so-called circulating tumor cells acquire properties
necessary to invade and grow in distant organs. The molecu-
lar characterization of these circulating cells is an innovative
approach to predict clinical behavior of tumors.7
Apart from the controversy about the various models and
theories of the metastatic process, the important thing is to
increase our knowledge thatwill allowus to treat patientswith
the most effective and less toxic treatments. The complexity
of biology will lead us to treat groups of patients based on the
disease prognosis and treatment prediction.
r e f e r enc e s
1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol
1995;13:8–10.
2. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body
radiotherapy for multisite extracranial oligometastases: ﬁnal
report of a dose escalation trial in patients with 1 to 5 sites of
metastatic disease. Cancer 2012;118:2962–70.
1507-1367/$ – see front matter © 2013 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Greater Poland Cancer Centre.
http://dx.doi.org/10.1016/j.rpor.2013.04.012
S28 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S27–S28
3. Halsted WSI. The results of radical operations for the cure of
carcinoma of the breast. Ann Surg 1907;46:1–19.
4. Fisher B. Laboratory and clinical research in breast cancer – a
personal adventure: the David A. Karnofsky memorial lecture.
Cancer Res 1980;40:3863–74.
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict
recurrence of tamoxifen-treated, node-negative breast cancer.
N Engl J Med 2004;351:2817–26.
6. Lussier YA, Khodarev NN, Regan K, et al. Oligo- and
polymetastatic progression in lung metastasis(es) patients is
associated with speciﬁc microRNAs. PLoS ONE 2012;7:
e50141.
7. Barbazan J, Alonso-Alconada L, Muinelo-Romay L, et al.
Molecular characterization of circulating tumor cells in
human metastatic colorectal cancer. PLoS ONE 2012;7:
e40476.
